Amended Statement of Ownership (sc 13g/a)
15 February 2020 - 8:37AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. 1)*
Provention
Bio, Inc.
(Name
of Issuer)
Common
Stock, $0.0001 par value per share
(Title
of Class of Securities)
74374N102
(CUSIP
Number)
December
31, 2019
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
[ ]
|
Rule
13d-1(b)
|
|
[ ]
|
Rule
13d-1(c)
|
|
[X]
|
Rule
13d-1(d)
|
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 74374N102
|
13G
|
Page
2 of 5 pages
|
|
1
|
Name
of Reporting Persons
Vactech
Oy
|
|
|
2
|
Check
the Appropriate Box if a Member of a Group
|
|
|
(a)
|
[ ]
|
|
|
(b)
|
[ ]
|
|
|
3
|
SEC
Use Only
|
|
|
4
|
Citizenship
or Place of Organization
Finland
|
Number
of
Shares
Beneficially
Owned
by
Each
Reporting
Person
With
|
5
|
Sole
Voting Power
2,000,000*
|
|
6
|
Shared
Voting Power
0
|
|
7
|
Sole
Dispositive Power
2,000,000*
|
|
8
|
Shared
Dispositive Power
0
|
|
9
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
2,000,000*
|
|
|
10
|
Check
Box if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]
|
|
|
11
|
Percent
of Class Represented by Amount in Row 9
4.2%*
|
|
|
12
|
Type
of Reporting Person
FI
|
*
Based on the information set forth in the Quarterly Report on Form 10-Q of Provention Bio, Inc. (the “Issuer”)
filed with the Securities and Exchange Commission on November 5, 2019, there were 47,638,361 shares of the Issuer’s common
stock, par value $0.0001 (the “Common Stock”), outstanding as of November 1, 2019. As of December 31, 2019
(the “Event Date”), Vactech Oy (the “Reporting Person”) may be deemed to beneficially own
an aggregate of 2,000,000 shares of Common Stock of the Issuer. Thus, as of the Event Date, for purposes of Rule 13d-3 under the
Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to beneficially own 4.2% of the shares of Common
Stock issued and outstanding. This filing constitutes as exit filing for the Reporting Person as Reporting person owns less
than 5% of the Common Stock of the Issuer.
SCHEDULE
13G
Item
1(a)
|
Name
of Issuer.
|
Provention
Bio, Inc.
Item
1(b)
|
Address
of Issuer’s Principal Executive Offices.
|
P.O.
Box 666, Oldwick, New Jersey 08858
Item
2(a)
|
Name
of Person Filing.
|
Vactech
Oy
Item
2(b)
|
Address
of Principal Business Office.
|
Biokatu
8, Tampere FIN 33520
Finland
Item
2(d)
|
Title
of Class of Securities.
|
Common
Stock, par value $0.0001 per share.
74374N102
If
this statement is filed pursuant to §§240.13d—1(b) or 240.13d—2(b) or (c), check whether the person
filing is a:
|
|
[X]
|
Not
Applicable
|
(a)
Amount beneficially owned: 2,000,000*
(b)
Percent of class: 4.2%*
(c)
Number of shares as to which such person has:
(i)
Sole power to vote or direct the vote: 2,000,000*
(ii)
Shared power to vote or direct the vote: 0
(iii)
Sole power to dispose or direct the disposition: 2,000,000*
(iv)
Shared power to dispose or direct the disposition: 0
*
Based on the information set forth in the Quarterly Report on Form 10-Q of Provention Bio, Inc. (the “Issuer”)
filed with the Securities and Exchange Commission on November 5, 2019, there were 47,638,361 shares of the Issuer’s common
stock, par value $0.0001 (the “Common Stock”), outstanding as of November 1, 2019. As of December 31, 2019
(the “Event Date”), Vactech Oy (the “Reporting Person”) may be deemed to beneficially own
an aggregate of 2,000,000 shares of Common Stock of the Issuer. Thus, as of the Event Date, for purposes of Rule 13d-3 under the
Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to beneficially own 4.2% of the shares of Common
Stock issued and outstanding. This filing constitutes as exit filing for the Reporting Person as Reporting person owns less
than 5% of the Common Stock of the Issuer.
Item
5
|
Ownership
of Five Percent or Less of a Class.
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than 5 percent of the class of securities, check the following [X].
Item
6
|
Ownership
of More than Five Percent on Behalf of Another Person.
|
Not
applicable.
Item
7
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
|
Not
applicable.
Item
8
|
Identification
and Classification of Members of the Group.
|
Not
applicable.
Item 9
|
Notice of Dissolution of Group.
|
Not
applicable.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURES
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
February 14, 2020
|
VACTECH OY
|
|
|
|
|
By:
|
/s/ Raimo Harju
|
|
Name:
|
Raimo
Harju, Chief Executive Officer of Vactech Oy
|
Schedule
13G Signature Page
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jul 2023 to Jul 2024